BNTX
BioNTech SE
98.60$
-0.5%
vs. previous close
Closing price · As of: Sep 29, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +4.9% | -140.5% | – | -139.1% | – | – | – | +546.7% | -65.0% | -243.0% | – | – | |
| – | +105.2% | -50.9% | +29.2% | -9.2% | +261.7% | -74.5% | +28.4% | +150.9% | +12.5% | -24.5% | +119.4% | – | |
| – | -8.4% | +14.8% | +23.9% | +102.5% | -42.5% | -6.0% | +45.2% | -13.1% | -13.6% | -5.4% | -8.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -377.6% | – | +957.7% | -128.3% | – | – | – | +28.1% | -129.5% | – | +802.2% | – | |
| – | +93.1% | -49.1% | +2.2% | -40.2% | +10.6% | +547.4% | -12.7% | -92.3% | +41.6% | -6.2% | -3.4% | – | |
| – | +130.1% | -11.8% | -90.1% | -34.6% | – | +102.1% | -102.0% | +3,633.9% | +163.8% | – | -103.9% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -100.0% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | -7.6% | +89.0% | -3.6% | -13.5% | +7.0% | – | -21.6% | – | |
| – | -99.0% | +167.2% | +191.7% | -64.9% | -6.6% | +79.5% | +2.9% | -6.1% | -0.3% | – | -513.4% | – | |
| – | – | – | – | -126.6% | – | – | +17.9% | -118.6% | – | – | -113.0% | – | |
| – | +73.1% | -143.1% | – | -148.4% | – | – | – | +15.9% | -70.7% | -304.3% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 29, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.